Introduction

• Brief introduction to the concept of pharmacovigilance and its importance in ensuring drug safety.
• Overview of the UAE’s healthcare landscape and the role of pharmacovigilance within it.

What is Pharmacovigilance?

• Definition of pharmacovigilance.
• Explanation of its goals – to detect, assess, understand, and prevent adverse effects or any other drug-related problems.

Pharmacovigilance in the UAE: An Overview

• Details on the regulatory framework governing pharmacovigilance services UAE, including the role of the Ministry of Health and Prevention (MOHAP).
• Introduction to the UAE's national pharmacovigilance center.

Regulatory Framework and Guidelines

• Discussion of specific regulations and guidelines that pharmaceutical companies in the UAE must follow.
• How these regulations align with international standards such as those set by the World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Reporting Adverse Drug Reactions (ADRs)

• Explanation of the process for reporting ADRs in the UAE.
• Importance of healthcare professionals and patients in reporting ADRs.
• Impact of ADR reporting on public health.

Technological Advancements in Pharmacovigilance

• How technology is being integrated into pharmacovigilance practices in the UAE, including the use of artificial intelligence (AI) and big data.
• Examples of local initiatives or systems that have been developed to improve pharmacovigilance.

Challenges in Pharmacovigilance

• Discussion of challenges faced by the pharmacovigilance system in the UAE, such as underreporting of ADRs and the need for more training and awareness.
• Strategies implemented to overcome these challenges.

The Future of Pharmacovigilance in the UAE

• Predictions or insights into future trends in pharmacovigilance in the UAE, such as increased international collaboration or further technological enhancements.
• Closing thoughts on how the UAE is poised to become a leader in pharmacovigilance in the Middle East.